Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G B Karlsson

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Virology|October 1, 1996
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120P B Fischer, G B Karlsson, T D Butters, et al.
The Journal of Biological Chemistry|October 28, 1994
N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processingF M Platt, G R Neises, G B Karlsson, et al.
British Journal of Cancer|September 24, 2004
Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell levelG B Karlsson, A Jensen, L F Stevenson, et al.
Journal of Virology|September 12, 1998
Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysB Etemad-Moghadam, G B Karlsson, M Halloran, et al.
Journal of Virology|October 29, 1997
Immunoglobulin V(H) usage during primary infection of rhesus monkeys with chimeric simian-human immunodeficiency virusesD H Margolin, K A Reimann, J Sodroski, et al.
Journal of Virology|October 1, 1996
A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeysK A Reimann, J T Li, R Veazey, et al.
Journal of Virology|September 1, 1995
The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 bindingP B Fischer, M Collin, G B Karlsson, et al.
Virology|March 24, 1999
Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency virusesK A Reimann, A Watson, P J Dailey, et al.
Journal of Virology|June 1, 1997
Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeysG B Karlsson, M Halloran, J Li, et al.
Journal of Virology|January 9, 1999
Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2)M Cayabyab, G B Karlsson, B A Etemad-Moghadam, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Virology|October 1, 1996
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120P B Fischer, G B Karlsson, T D Butters, et al.
The Journal of Biological Chemistry|October 28, 1994
N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processingF M Platt, G R Neises, G B Karlsson, et al.
British Journal of Cancer|September 24, 2004
Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell levelG B Karlsson, A Jensen, L F Stevenson, et al.
Journal of Virology|September 12, 1998
Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysB Etemad-Moghadam, G B Karlsson, M Halloran, et al.
Journal of Virology|October 29, 1997
Immunoglobulin V(H) usage during primary infection of rhesus monkeys with chimeric simian-human immunodeficiency virusesD H Margolin, K A Reimann, J Sodroski, et al.
Journal of Virology|October 1, 1996
A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeysK A Reimann, J T Li, R Veazey, et al.
Journal of Virology|September 1, 1995
The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 bindingP B Fischer, M Collin, G B Karlsson, et al.
Virology|March 24, 1999
Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency virusesK A Reimann, A Watson, P J Dailey, et al.
Journal of Virology|June 1, 1997
Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeysG B Karlsson, M Halloran, J Li, et al.
Journal of Virology|January 9, 1999
Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2)M Cayabyab, G B Karlsson, B A Etemad-Moghadam, et al.
Pageof 3